AcelRx Reaches Licensing Deal For DZUVEO In Europe And In-licensing Deal For Two Products In US

AcelRx Pharmaceuticals Inc. (ACRX) said that it has reached agreements with Laboratoire Aguettant providing Aguettant with a license to commercialize DZUVEO in Europe, and providing AcelRx with two pre-filled syringe product candidates for the U.S.

As per the DZUVEO licensing deal, Aguettant will have the right to commercialize DZUVEO in Europe.

AcelRx is entitled to receive up to about $55 million in a combination of up-front and sales-based milestone payments at various annual sales levels from Aguettant, along with revenue share payments ranging from 35% to 45% of net sales.

AcelRx will manufacture and supply DZUVEO to Aguettant at an agreed supply price.

In a separate licensing agreement, AcelRx obtained the rights to file NDAs, commercialize in the United States two of Aguettant's EU-approved, pre-filled syringe products - ready-to-use ephedrine and phenylephrine.

Aguettant has the right to receive up to $24 million in sales-based milestone payments, at various annual sales levels up to $60 million, along with revenue share payments of 40 to 45% of the net sales of the two pre-filled syringe products, if approved in the U.S. by the Food and Drug Administration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT